OOIR: Observatory of International Research

Papers

(The TQCC of JACC-Heart Failure is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Clinical Implications of the P.V142I TTR Variant	276
Pulmonary Artery Catheter Timing and Outcomes for Patients With Cardiogenic Shock	221
Reply	136
Reply	116
Examination of Initiation Patterns for Sacubitril/Valsartan Among Older Adults With HFrEF in the United States	99
CHIEF Effects of Sodium Glucose Co-Transporter Inhibitors on Health-Related Quality of Life in Heart Failure	99
Long-Term Effects of Sotatercept on Right Ventricular Function	91
Developing a System for Best Performance for Cardiac Transplantation	84
Reply	77
Reply	76
Editorial Board	74
Curing Ourselves of Toxic Positivity for Hospital-at-Home	73
Correction	73
Growth Hormone Replacement Therapy in Heart Failure With Reduced Ejection Fraction	72
Wearable Remote Patient Monitoring Devices	68
Myeloperoxidase in Heart Failure With Preserved Ejection Fraction	67
Associations Between Urinary Metal Levels and Incident Heart Failure	67
Full issue PDF	65
Clinical Inertia Disturbs the Harmonious Treatment of Heart Failure	62
Revisiting ICD Therapy for Primary Prevention	62
Opportunities for Change in Home Health Care in Heart Failure	60
Exercise Blood Pressure in Heart Failure With Preserved and Reduced Ejection Fraction	60
Tachycardia and Atrial Fibrillation-Related Cardiomyopathies	56
Early U.S. Heart Transplant Experience With Normothermic Regional Perfusion Following Donation After Circulatory Death	55
Predictors of Incident Heart Failure Diagnosis Setting	55

Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status	55
Racial and Genetic Differences in Presentation of Transthyretin Amyloid Cardiomyopathy With Impaired Left Ventricular Function	55
Eating to Prevent Both Heart and Planetary Failure	53
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype	52
Recognizing the Top Reviewers and Top Authors of JACC: Heart Failure	51
Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome	49
Challenges Addressing Prognosis in Advanced Heart Failure	48
Geographic Variation in the Quality of Heart Failure Care Among U.S. Veterans	48
Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia	48
Practical Application of Pressure-Volume Loops and Cardiac Energetics to Improve Care Delivery in Pulmonary Hypertension	47
Hospital at Home as a Novel Care Strategy for Worsening Heart Failure	46
Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status	44
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction	44
Rationale and Design of the HeartShare/AMP-HF Deep Phenotyping Study to Improve Understanding of Heart Failure With Preserved Ejection Fraction	42
Heart Failure With Preserved Ejection Fraction	40
Reply	39
Closing the Gap, A Commentary on Sex Differences in Efficacy of Multidomain Rehabilitation Among Older Adults With Acute Heart Failure	39
Inhibiting Both Neprilysin and Phosphodiesterase Type 9	39
Smartphone-Based Recognition of Heart Failure by Means of Microelectromechanical Sensors	39
Eplerenone for Nonobstructive Hypertrophic Cardiomyopathy	38
High NT-proBNP in Heart Failure	38
The Impact of Social Determinants of Health on Timely Detection in Transthyretin Cardiac Amyloidosis	37
Effects of Acute Phase Intensive Exercise Training in Patients With Acute Decompensated Heart Failure	37
Clinical Utility of the H2FPEF Score in Patients With Early Atrial Fibrillation	36
GDF-15 in Cardiovascular Disease	36
The Path Toward a More Equitable Transplant System	36
Obesity and Heart Failure in Patients With a Reduced Ejection Fraction	35
Prognosis for Acute Myocarditis	35
Peripheral Venous Pressure Measured With a Novel Miniature Transducer in Heart Failure Patients	35
Cardiopulmonary Exercise Testing With Exercise Echocardiography to Assess Treatment Response in Transthyretin Amyloid Cardiomyopathy	35
Compensation Models in Heart Failure	34
Full Issue PDF	34
NT-proBNP	34
Endothelin Receptor Antagonists and Risk of Heart Failure in CKD	34
Hyperkalemia-Related Heart Failure Therapy Discontinuation and the Association With Outcomes in Patients With Heart Failure	34
Are We Waiting Too Long to Implant Cardiac Resynchronization Therapy Devices in Patients With Heart Failure and Reduced Left Ventricular Function?	33
From Dispensing Pills to Building Pillars	33
Racial and Genetic Differences	32
Impact of SGLT2 Inhibitors on Serum Sodium in Heart Failure With Reduced Ejection Fraction	31
Reply	31
Advanced Heart Failure in the Cardiac Intensive Care Unit	31
Thank You for the Privilege	30
Increasing the Utilization of Sac/Val in Elderly HFrEF Patients Eligible for ARNI Treatment	30
A Woman's Work Is Never Done	30
Absence of Atrial Fibrillation Reduction in REDUCE LAP-HF II	29
Heart Failure in Women	29
Body Composition and Survival in Patients With Heart Failure	28
Treatment Differences in Medical Therapy for Heart Failure With Reduced Ejection Fraction Between Sociodemographic Groups	28
Influence of Impaired Conduction on Exercise Hemodynamics in Patients With Preserved Ejection Fraction	28
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events	28

Framework for Analytical Validation of DHT-Based Actigraphy and Signal Measures in HF Trials	28
Practical Guidance for Hemodynamic Assessment by Right Heart Catheterization in Management of Heart Failure	28
STRONG-HF	28
Challenges in Cardiomyopathy Gene Therapy Clinical Trial Design	27
Value of Invasive Hemodynamic Assessments in Patients Supported by Continuous-Flow Left Ventricular Assist Devices	27
Every Journey Needs a Guide	27
Reevaluating Growth Hormone Therapy in HFrEF	27
Facts and Fallacies of Body Composition Analysis in Heart Failure	26
Early Longitudinal Change in Heart Failure Health Status Following Initiation of Canagliflozin	25
Risk Factors and Temporal Trends of Maternal Heart Failure	25
SGLT2 Inhibitors and Serious Renal Events Among Patients With Heart Failure With Reduced Ejection Fraction	25
Therapeutic Options in Ambulatory Advanced Heart Failure	25
Reply	25
Upper Body Hypoxemia During ECMELLA	24
Winning the Battle of Timely Guideline-Directed Medical Therapy Titration	24
Distinct Impact of Noncardiac Comorbidities on Exercise Capacity and Functional Status in Chronic Heart Failure	24
Pregnancy-Induced Hypertensive Disorder and Risks of Future Ischemic and Nonischemic Heart Failure	24
Natriuretic Peptides and Stratification for ICD Therapy in Nonischemic Heart Failure	24
SGLT2 Inhibitors in Patients With Cancer Therapy-Related Cardiotoxicity	23
Temporal Characteristics of Device-Based Individual and Integrated Risk Metrics in Patients With Chronic Heart Failure	23
Left Ventricular Dimensions and Clinical Outcomes With a Fully Magnetically Levitated Left Ventricular Assist Device	23
National Trends and Disparities in Heart Failure Hospitalizations and Inpatient Outcomes Between 2010-2022	23
Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure	23
Understanding and Investigating Sex-Based Differences in Heart Transplantation	22
Seated Pulmonary Artery Pressure Monitoring in Patients With Heart Failure	22
Continuum of Preshock to Classic Cardiogenic Shock in the Critical Care Cardiology Trials Network Registry	22
Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction	22
Management of Heart Failure–Related Cardiogenic Shock	22
Obesity and Weight Loss Strategies for Patients With Heart Failure	22
Guideline Recommendations for Sudden Cardiac Death Prevention in Patients With Hypertrophic Cardiomyopathy	22
Diabetes Therapy With SGLT2i After Heart Transplant	22
Real-World Experience and 36-Week Outcomes of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten	22
Treatment of Obesity in Heart Failure	21
Smoking Cessation Reduces the Risk of Heart Failure	21
Full issue PDF	21
Tafamidis in Octogenarians	21
Moving From Prompts to Praxis With Remote Monitoring	21
Editorial Board	21
Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes	20
Redefining Pre–Heart Failure With Cardiac Biomarkers	20
Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Tafamidis in Cardiac Amyloidosis	20
Upgrading Right Ventricular Pacing to Cardiac Resynchronization in HFrEF Patients Improves Symptoms and Functional Outcomes	20
Plasma Amyloid-β in Relation to Cardiac Function and Risk of Heart Failure in General Population	20
Illuminating a Hidden Risk	20
Beyond Coronary Atherosclerosis	20
Venting the Venous Circulation	20
Identifying Predictors for Heart Failure Outcomes in Phospholamban p.(Arg14del)–Positive Individuals	20
Effective and Cost-Conscious Utilization of SGLT2 Inhibitors	19
Any Cardiac Influence of the Structural and Functional Brain Changes in Patients With Takotsubo Syndrome?	19
Instructions for Authors	19
Walking the Line Between Failure and Remission	19
Full issue PDF	19
To Infinity and Beyond	19
Bounded Rationality and Clinical Guidance Documents for Heart Failure	19
Jump Starting the Heart	19
Setting the Diagnosis of Heart Failure	19
Isolating Noise From Signals in the Air	19
To ‘Plant or Not to ‘Plant, That Is the Question	19
Critical Importance of Genetic Screening in Family Members	19
The Jury Is Still Out on A-Type Natriuretic Peptide Deficiency Relative to B-Type Natriuretic Peptides	18
Contemporary Epidemiology, Management, and In-Hospital Outcomes of Acute Myocarditis	18
Expanded Definition of Worsening Heart Failure	18
Association of High-Density Lipoprotein Parameters and Risk of Heart Failure	18
Unreliable HFpEF Diagnosis by H2FPEF in AF	18
Perirenal Adipose Tissue Is Associated With Renal Dysfunction and Abnormal Hemodynamics in Patients With HFpEF	18
The p.Asn271Ile Variant in the TNNT2 Gene Is Associated With Low-Risk Late-Onset Hypertrophic Cardiomyopathy	18
Transendocardial Injection of Expanded Autologous CD34+ Cells After Myocardial Infarction	18
Toward a Streamlined Optimization Protocol for Patients With Heart Failure With Reduced Ejection Fraction	18
Pressure From Within and Without in Heart Failure With Preserved Ejection Fraction	17
Reply	17
Physical Activity Trajectories Preceding Incident Heart Failure	17
Full Issue PDF	17
Bereavement and Mortality in Heart Failure	17
Safety of Right and Left Ventricular Endomyocardial Biopsy in Heart Transplantation and Cardiomyopathy Patients	17
Patterns of Left Ventricular Regional Wall Motion Abnormalities After Brain Death and Their Clinical Significance	17
Istaroxime in HFpEF	17
A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of HFrEF	17
From Better Models to Better Care	17
Correction	16
GLP-1 Receptor Agonists in Heart Failure With Reduced Ejection Fraction	16

Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure	16
The Link Between Heart Failure and Neurodegeneration	16
Hemodynamic-Guided Heart Failure Management in Patients With Either Prior HF Hospitalization or Elevated Natriuretic Peptides	16
Diet and Heart Failure	16
Pulmonary Artery Denervation for Combined Pre– and Post–Capillary Pulmonary Hypertension	16
Depressive Symptoms and Incident Heart Failure Risk in the Southern Community Cohort Study	16
Gamified Behavioral Science Intervention to Enhance Trial Enrollment	16
Refining Endpoint Measures in Clinical Trials for Hypertrophic Cardiomyopathy	16
Articulating the JACC Journals’ Direction in Times of Global Change	16
Gender and Race Differences in HeartMate3 Left Ventricular Assist Device as a Bridge to Transplantation	16
Impact of Female Sex on Cardiogenic Shock Outcomes	15
Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States	15
Rationale and Design of the Dapagliflozin Effect on Cardiovascular Events in Acute Heart Failure (DAPA ACT HF)-TIMI 68 Trial	15
HFpEF Scores	15
Shedding Light on the Darkness of MYH7 Cardiomyopathies	15
Cardiac Magnetic Resonance in the Evaluation and Management of Nonischemic Cardiomyopathies	15
Impact of Coronary Artery Disease in Women With Newly Diagnosed Heart Failure and Reduced Ejection Fraction	15
Global Heart Failure Trends in Young Adults	15
Streamlined Heart Failure Optimization Protocol for Patients With Reduced Left Ventricular Ejection Fraction	15
All That Glitters Is Not Gold	15
Targeting Inflammation in Heart Failure Prevention	15
Mechanically Reducing Cardiac Preload With the preCARDIA System in Acutely Decompensated Heart Failure	15
Initial Experience With Aeson Total Artificial Heart in Cardiogenic Shock Patients on Extracorporeal Life Support	15
Navigating Advanced Heart Failure in the Shadow of Primary Graft Dysfunction	15
Disease Penetrance in Genotype-Positive But Clinically Unaffected Relatives From Families With Dilated Cardiomyopathy	15
Automated Identification of Heart Failure With Reduced Ejection Fraction Using Deep Learning-Based Natural Language Processing	15
Deactivation of Left Ventricular Assist Devices at the End of Life	15
Prevalence and Incidence of Pre-HF Among Hispanics/Latinos	15
Reply	14
Correction	14
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction	14
Reply	14
Exertional Dyspnea Can Now Be Graded Using Normative Reference Equations	14
Low Serum Ferritin Might Predict Incident Heart Failure	14
Patient Preference Should Take Precedence in Status 2 Listing for Heart Transplantation	14
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy	13
Nonsteroidal and Steroidal Mineralocorticoid Antagonists	13
The Enigma of Natriuretic Peptides	13
Multifactorial Predisposition in Biopsy-Proven Autoimmune and Viral Myocarditis	13
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved Trial	13
Navigating the Global Burden of Pulmonary Arterial Hypertension	13
Medication Optimization Clinic	13
Reducing Pediatric Heart Failure Readmissions	13
Early Reduction of Pulmonary Artery Pressures Is Associated With Improved Mortality Among Medicare Beneficiaries With Heart Failure	13
Heart Failure With Preserved Ejection Fraction in Patients With Atrial Fibrillation	12
Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction	12
Effect of PCI on Health Status in Ischemic Left Ventricular Dysfunction	12
Standardizing Histopathological Evaluation of Resected Myocardium in Obstructive Hypertrophic Cardiomyopathy	12
The Lure of Cardiac Metabolism in the Diagnosis, Prevention, and Treatment of Heart Failure	12
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF	12
Pre–Heart Failure Longitudinal Change in a Hispanic/Latino Population-Based Study	12
Redefining Boundaries in Heart Failure Care	12
Aging in Heart Failure	12
Thin Evidence, Heavy Need	12
Mineralocorticoid Receptor Antagonist Use in Hypertension to Prevent Heart Failure	12
Contemporary American and European Guidelines for Heart Failure Management	12
Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy	12
Can Sensor Implantation Alone Reduce Heart Failure Hospitalizations Without Need for Structured Management Based on its Data?	11
Pregnancy as a Sentinel Event	11
Iron Deficiency Definition and Management in Patients With Heart Failure	11
Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction	11
Correction	11
Cost and Value in Contemporary Heart Failure Clinical Guidance Documents	11
Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure Patients	11
Reflections on Early Rehabilitation in Acute Heart Failure	11
Temporal Trends, Risk Factors, and Clinical Outcomes of De Novo Lymphoproliferative Disorders After Heart Transplantation	11
Concomitant Surgical Procedures and Aspirin Avoidance With Left Ventricular Assist Device Therapy	11
Reply	11
BMI in HFpEF	11
Information for Authors	11
Better 3 Hours Too Soon Than 1 Minute Late	11
Full issue PDF	11
REPLY	11
Guideline-Recommended Therapy Following Hospitalization for Heart Failure	11
Management of Patients With Impella 5.5 Left Ventricular Assist Devices on a Cardiovascular Stepdown Unit	11
Frailty Status Modifies the Efficacy of ICD Therapy for Primary Prevention Among Patients With HF	11
Hypertrophic Cardiomyopathy With Midventricular Obstruction Is Not Nonobstructive Hypertrophic Cardiomyopathy	11
Fibrosis Biomarkers Predict Cardiac Reverse Remodeling	11
Coronary Artery Disease Is Still a Major Cause of Heart Failure	11
m-Health Based Cardiac Rehabilitation Program for Management of Older Patients With HFpEF	11
Real-World Outcomes of SGLT2 Inhibitors in Very Elderly Patients With Heart Failure With Preserved Ejection Fraction	10
24-Month Outcomes of Endovascular Baroreflex Amplification With the MobiusHD Device in Heart Failure With Reduced Ejection Fraction	10
Pulse Pressure Augmentation During Exercise	10
Encouraging Data Encourage More Research on Optimal Medical Therapy for Patients With HFrEF	10
Correction	10
Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction	10
Left Atrial-to-Coronary Sinus Shunting in Heart Failure With Mildly Reduced or Preserved Ejection Fraction	10
Sex, Temporary Mechanical Circulatory Support, and Heart Transplantation	10
Measures to Improve Trial Enrollment	10
Barriers and Facilitators to Prescribing Guideline-Directed Medical Therapy for Heart Failure in the Indian Health Service	10
The HeartMate 3 Risk Score	10
Association of Extracoronary Calcification and Incident Heart Failure in the Multiethnic Study of Atherosclerosis (MESA)	10
But Is All Post-Transplant Lymphoproliferative Disorder Created Equal?	10
Reply	10
Heart Failure and the Risk of Stroke	10